RIBOZYME AND OMICS
Hepatocellular carcinoma followed by expanded indications
Rznomics announced on the 12th that it has applied to the U.S. Food and Drug Administration (FDA) for phase 1 and 2a clinical trials for glioblastoma of "RZ-001. This is to expand the indication following the ongoing clinical trial for hepatocellular carcinoma.
Glioblastoma is a malignant tumor that occurs in the brain. The average survival period is less than 15 months and the five-year survival rate is less than 3%. There is no clear cure yet.
Based on RNA trans-splicing ribozyme, Rznomics is developing a technology that removes target RNA and expresses the desired gene at the same time. RZ-001 delivers ribonucleic acid substituent to adenovirus. It targets telomerase (hTERT) RNA, which is specifically expressed in cancer cells, and expresses a gene that induces anticancer action.
Therefore, it is universally applicable to all carcinomas in which target substances are expressed. Non-clinical results through glioblastoma animal models showed excellent anticancer ability. Rznomics is developing treatments such as Alzheimer's, hereditary retinal biological degeneration, and retinal syndrome using platform technology as well as anticancer drugs.
Seong-wook Lee, CEO of Rznomics, said, "Even in a difficult bio-industry environment, candidate substances under development are entering the clinical stage smoothly," adding, "We will do our best to provide new treatment opportunities to patients as soon as possible."